BioLife Sciences Valuation
| BLFE Stock | USD 0.0001 0.00 0.00% |
BioLife Sciences seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of BioLife Sciences from analyzing the firm fundamentals such as Net Income of (456.87 K), total debt of 398 K, and Current Valuation of 1.01 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioLife Sciences' price fluctuation is very steady at this time. Calculation of the real value of BioLife Sciences is based on 3 months time horizon. Increasing BioLife Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioLife pink sheet is determined by what a typical buyer is willing to pay for full or partial control of BioLife Sciences. Since BioLife Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLife Pink Sheet. However, BioLife Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The real value of BioLife Pink Sheet, also known as its intrinsic value, is the underlying worth of BioLife Sciences Company, which is reflected in its stock price. It is based on BioLife Sciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioLife Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioLife Sciences helps investors to forecast how BioLife pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLife Sciences more accurately as focusing exclusively on BioLife Sciences' fundamentals will not take into account other important factors: BioLife Sciences Total Value Analysis
BioLife Sciences is currently forecasted to have valuation of 1.01 M with market capitalization of 11.45 K, debt of 398 K, and cash on hands of 15.62 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioLife Sciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.01 M | 11.45 K | 398 K | 15.62 K |
BioLife Sciences Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of BioLife indicates not a very effective usage of assets in December.BioLife Sciences Profitability Analysis
Net Loss for the year was (456.87 K) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioLife Sciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioLife Sciences and how it compares across the competition.
About BioLife Sciences Valuation
The pink sheet valuation mechanism determines BioLife Sciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of BioLife Sciences. We calculate exposure to BioLife Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioLife Sciences's related companies.Bio Life Sciences Corp. develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology. Bio Life Sciences Corp. was incorporated in 2018 and is based in Mississauga, Canada. Biolife Sciences operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3 people.
8 Steps to conduct BioLife Sciences' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioLife Sciences' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioLife Sciences' valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioLife Sciences' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioLife Sciences' revenue streams: Identify BioLife Sciences' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioLife Sciences' industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioLife Sciences' growth potential: Evaluate BioLife Sciences' management, business model, and growth potential.
- Determine BioLife Sciences' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioLife Sciences' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
BioLife Sciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as BioLife Sciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -1.7 M |
Complementary Tools for BioLife Pink Sheet analysis
When running BioLife Sciences' price analysis, check to measure BioLife Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Sciences is operating at the current time. Most of BioLife Sciences' value examination focuses on studying past and present price action to predict the probability of BioLife Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Sciences' price. Additionally, you may evaluate how the addition of BioLife Sciences to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |